In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes ...

Investing.com -- Shares of Ascendis Pharma (NASDAQ:ASND) rose as much as 8.5% to a new high. On January 20th RBC Capital updated its model based on new guidance from the company, raising its price ...

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ...

Chronic time pressure strains mental health, suggesting relief may come from loosening time’s control rather than managing it ...

Eco-design, Patient-centric design, Delivery & device innovations and Packaging innovation.

VANCOUVER, BC / ACCESS Newswire / January 22, 2026 / Kingfisher Metals Corp. (TSXV:KFR)(FSE:970)(OTCQB:KGFMF) ("Kingfisher" or the "Company") is pleased to announce final assay results from the 2025 d ...

Kingfisher Metals Corp. is pleased to announce final assay results from the 2025 drilling program at the HWY 37 Project. The 933 km2 HWY 37 Project is located within the Golden Triangle, . Drillhole ...